Emergent Biosolutions
EBS
215 hedge funds and large institutions have $1.23B invested in Emergent Biosolutions in 2016 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 85 increasing their positions, 75 reducing their positions, and 23 closing their positions.
43% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 23
13% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 75
4% more funds holding
Funds holding: 206 → 215 (+9)
0.07% more ownership
Funds ownership: 85.03% → 85.1% (+0.07%)
7% less capital invested
Capital invested by funds: $1.32B → $1.23B (-$90.3M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
58% less call options, than puts
Call options by funds: $2.64M | Put options by funds: $6.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$23.8M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$14M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.8M |
| 4 |
TA
Teachers Advisors
New York
|
+$7.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$26.9M |
| 2 |
Bank of New York Mellon
New York
|
-$17.8M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$8.94M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$5.99M |
| 5 |
FMA
Fiduciary Management Associates
Chicago,
Illinois
|
-$5.52M |
EBS Hedge Fund Activity: Q1 2016 in Review
215 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2016, worth a combined $1.23B — down 6.8% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new EBS positions and 23 closed out — a net gain of 10 holders — while 85 added to existing stakes and 75 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $23.8M. The largest seller was Broadfin Capital, exiting entirely with an estimated $26.9M sold.
- 215 institutional investors held Emergent Biosolutions (EBS) as of Q1 2016, up from 206 in Q4 2015.
- Funds reported $1.23B of Emergent Biosolutions stock for Q1 2016, down 6.8% quarter-over-quarter.
- 33 funds opened new Emergent Biosolutions positions in Q1 2016 and 23 closed out, a net change of +10 holders.
- The largest Emergent Biosolutions buyer in Q1 2016 was Acadian Asset Management, an estimated $23.8M added.
- The largest Emergent Biosolutions seller in Q1 2016 was Broadfin Capital, an estimated $26.9M sold.
Based on aggregated 13F filings for Q1 2016.